



Q3 2012 RESULTS

INTERMONTE November 22th, 2012

Company Presentation



Disclaimer

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.







- 2. CYNOSURE PUBLIC OFFERING
- 3. EL.EN. GROUP
- 4. 9 M 2012 FINANCIAL RESULTS
- **5.** 2012 GUIDANCE
- 6. MULTIPLES AND COMPARABLES





The Global Laser Market







LASER

Light Amplification Stimulated by Emission of Radiation

MEDICAL LASER Systems

INDUSTRIAL LASER Systems



The MEDICAL Laser Market



The AESTHETIC Laser Market Shares



Revenues in \$ M

	2008	2009	2010	2011	2012(**)
El.En. Aesthetic/Medical	\$ 97,4	\$ 72 <i>,</i> 8	\$ 89,9	\$ 88,1	\$ 94,8
Cynosure	\$ 139,0	\$ 72,5	\$ 81,5	\$ 110,2	\$ 147,4
Peer group Total (*)	\$ 924,7	\$ 661,0	\$ 710,2	\$ 850,2	\$ 943,6
% El.En.	10,5%	11,0%	12,7%	10,4%	10,0%
% Cyno	15,0%	11,0%	11,5%	13,0%	15,6%
% El.En. Group	25,6%	22,0%	24,1%	23,3%	25,7%

(*)

Lumenis (Aesth) - estimated

Cynosure (CYNO)

Cutera (CUTR)

Palomar (PMTI)

Syneron (ELOS)

Solta Medical (SLTM)

Biolase (BIOL)

El.En. (aesth w/o Cyno)



The INDUSTRIAL Laser Market

Laser Sources Market

Revenues (\$M)



2008 2009 2010 2011 2012

Source: Laser focus World





Cynosure Public Offering







El.En.: Offering 600k its Cynosure's shares

Greenshoe 240k+240k shares



Capital gain 5,6 mm of euro



El.En.'s share of Cynosure falls below 20% to 13% Cynosure is no longer fully consolidated





Cynosure

Strategic cooperation

R&D and distribution	Smartlipo MPX – Triplex - Cellulaze- Fractional CC						
	2008	2009	2010	2011	9M 2012		
Sales of ex Cyno El.En. group to Cynosure (Euro 000)	12.560	4.365	4.167	5.434	3.500		
% on ex Cyno Aesthetic sales	16,8%	7,8%	6,0%	8,0%	6,3%		







El.En. Group









Group Overview

High -Tech Industrial Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications

Know-how based on 30 years stratification of multidisciplinary experience

September, 30th 2012 (w\o Cynosure): Consolidated Revenues of €108 mln, up 11% YoY, 774 employees

Global positioning



Strategic Strengths

Multidisciplinary and multifacility R&D activity: sources, systems, applications.

Covering both Medical and Industrial laser markets

Industrial

✓ Combine High tech laser source development with flexible production facilities in high growth areas

Medical


- ✓ Maximize market penetration by multi brand approach
- ✓Open new market segments by developing innovative applications
- ✓ Leverage worldwide distribution







Consolidated Revenues





Consolidated EBIT





R&D Activity

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser-tissue interaction

Laser systems for regenerative medicine

Laser and ultrasound combination systems for minimally invasive surgery

New applications of cutting edge CO₂ platform: MonaLisa Touch, ENT

High power surgical lasers for BPH: Ho:YAG and Tm

Improvements in laser lipolysis and cellulite treatment systems: Cellulaze

Cutting and welding applications for 5 axes laser systems

Compact RF medium power sources

MILORDS project: robot-controlled laser systems for surgical applications



R&D expenses

	30/09/11	30/09/12	Var.%
R&D expenses	10.876	13.197	21.3%
Percentage on group revenues	7.4%	6.9%	
Grants	1.009	1.523	50.9%

- √ 70 Research engineers
- ✓ 4 R&D labs:

Florence, Milan, Naples, Jena





Medical/Aesthetic

Aesthetic

Hair Removal

Vascular Lesions

Skin Rejuvenation

Pigmented Lesions

Treatment of Cellulite

Acne

Tattoo Removal

Anti - Aging

LaserBody Sculpting

Removal of Unwanted Fat













Medical

ENT

Gynaechology

Urology

Endovascular

Onchology


Dermatology


Psoriasis and Vitiligo

Dentistry

Therapy









9M 2012 Financial Results





Consolidated P&L

(6)	30/09/11		30/09/12		Var.%
	unaudited		unaudited		
Revenues	147.330	100,0%	191.112	100,0%	29,7%
Gross margin	77.202	52,4%	99.910	52,3%	29,4%
EBITDA	7.853	5,3%	20.094	10,5%	155,9%
EBIT	(65)	0,0%	12.155	6,4%	
Income before taxes	(768)	-0,5%	11.427	6,0%	
	31/12/11		30/09/12		
			unaudited		
Net financial position	53.035		68.651		



Consolidated P&L (w/o Cynosure)

6	30/09/11		30/09/12		Var.%
	unaudited		unaudited		
Revenues	97.718	100,0%	108.310	100,0%	10,8%
Gross margin	48.561	49,7%	51.876	47,9%	6,8%
EBITDA	7.599	7,8%	9.307	8,6%	22,5%
EBIT	3.457	3,5%	5.571	5,1%	61,2%
Income before taxes	2.795	2,9%	4.615	4,3%	65,1%
	31/12/11		30/09/12		
			unaudited		
Net financial position	1.764		7.805		




El.En. – Revenues breakdown by business





- Service
 Medical
 Industrial
- Medical
 Aesthetic
 Surgical CO₂
 Physiotherapy
 Dental



Sept. 30th, 2011 Sept. 30th, 2012

2012: +11%

Cynosure

Medical

Aesthetic Service



El.En. – Medical and Aesthetic



Industrial

Service

Medical

Accessories


Other Medical Lasers

Dental

Aesthetic

Physiotherapy

■ Surgical CO2



Sept. 30th, 2011

Sept. 30th, 2012

Cynosure

Medical

Aesthetic

2012: +15%



El.En. – Industrial





Sept. 30th, 2011

Sept. 30th, 2012

Cynosure

Medical Aesthetic Service 2012: +2%





Guidance









Forecast

Sales: ≥ +10%

EBIT%: ≥ 5%







Multiples and comparables





El.En. w\o Cynosure multiples

Stockholder's Equity per share	25
Price / Book Value Adj.	0,64
EV /EBIT (70% EBIT w/o Cynosure)	4,22
EV / Sales (70% Sales w/o Cynosure)	0,22

El.En. Market Cap.	77,2 @ €16
Net financial position	7,8 @ 30/09/12
Market value of 2,9 mm Cynosure shares	47,4 @ \$20,5 (Euro/Usd=1,27)
Enterprise Value	21,9 @ 30/09/12
Stockholder's Equity pertaining to parent company, (with Cynosure shares at market value)	121,2 @ 30/06/12



Comparables


9 Months	Price	Revenue	Var.% Revenue	EBIT	MK.Cap.	EV	EV/Sales (*)	EV/EBIT (*)	P/Book Value
Medical/Aesthetic									
Syneron	\$7,72	\$190.862	14%	\$(6.071)	\$274.110	\$158.302	0,62	n.a.	1,27
Palomar	\$7,53	\$57.145	-29%	\$(8.247)	\$147.480	\$63.314	0,83	n.a.	0,99
Solta Medical	\$2,41	\$104.744	26%	\$(36.615)	\$165.210	\$154.415	1,11	n.a.	1,52
Cutera	\$8,74	\$54.744	31%	\$(7.895)	\$123.460	\$43.331	0,59	n.a.	1,41
Biolase	\$1,79	\$38.276	7%	\$(3.723)	\$55.920	\$56.814	1,11	n.a.	5,42
Industrial									
IPG Photonics Co.	\$55,50	\$417.498	19%	\$161.629	\$2.850.000	\$2.483.903	4,46	11,53	3,91
Rofin-Sinar	\$19,16	\$408.551	-11%	\$39.279	\$544.120	\$442.957	0,81	8,46	1,10
Prima Industrie	€9,46	€245.379	21%	€11.239	€81.750	€222.522	0,68	14,85	1,00
Cynosure	\$20,50	\$110.546	45%	\$7.606	\$337.695	\$259.022	1,76	25,54	2,47
El.En. (ex Cynosure) (1)	€16,00	€108.310	11%	€5.571	€77.190	€21.950	0,22	4,22	0,64

^(*) Sales and Ebit annualized



⁽¹⁾ EV and multiplies as for previous slide

El.En. and Cynosure stock performance







El.En. SPA

Enrico ROMAGNOLI

Investor Relations Manager

tel. +39 055-8826807

E-mail: finance@elen.it

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI

Financial Communication

Tel. +39 06-6797849 / +39 06-69923324

E-mail: b.fersini@polytemshir.it

POLYTEMS HIR SRL

Roberta MAZZEO

Press office

Tel. +39 06-6797849 / +39 06-69923324

E-mail: r.mazzeo@polytemshir.it